Getagraph.com logo
S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.36%) $91.45

Sanntidsoppdatering for Supernus Pharmaceuticals [SUPN]

Børs: NASDAQ Sektor: Healthcare Industri: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

4 days till quarter result
(amc 2024-05-08)

Expected move: +/- 4.43%

BUY
66.67%
return 2.21%
SELL
33.33%
return 3.32%
Sist oppdatert3 mai 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

1.85% $ 30.83

SELG 115245 min ago

@ $27.40

Utstedt: 14 feb 2024 @ 15:30

Avkastning: 12.52%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -0.36 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States...

Stats
Dagens volum 353 896
Gjennomsnittsvolum 394 938
Markedsverdi 1.69B
EPS $0 ( 2024-02-27 )
Neste inntjeningsdato ( $0.390 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 1 541.50
ATR14 $0.0330 (0.11%)
Insider Trading
Date Person Action Amount type
2024-03-21 Bhatt Padmanabh P. Buy 14 491 Common Stock
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Employee Stock Option (Right to Buy)
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Common Stock
2024-03-20 Bhatt Padmanabh P. Sell 400 Employee Stock Option (Right to Buy)
2024-03-20 Bhatt Padmanabh P. Buy 400 Common Stock
INSIDER POWER
38.23
Last 100 transactions
Buy: 802 366 | Sell: 356 762

Volum Korrelasjon

Lang: 0.29 (neutral)
Kort: 0.28 (neutral)
Signal:(67.569) Neutral

Supernus Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
CD0.91
BRKR0.889
VTYX0.888
SOUN0.887
ICLR0.885
FGEN0.881
CRTD0.88
LEXX0.88
CELH0.879
CRNC0.878
10 Mest negative korrelasjoner
PCRX-0.866
METX-0.862
LLNW-0.859
DCRC-0.858
SABR-0.853
SFET-0.848
NBRV-0.842
MTEX-0.834
ASRVP-0.834
ZENV-0.831

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Supernus Pharmaceuticals Korrelasjon - Valuta/Råvare

The country flag -0.29
( neutral )
The country flag -0.12
( neutral )
The country flag 0.00
( neutral )
The country flag -0.33
( neutral )
The country flag -0.07
( neutral )
The country flag 0.73
( moderate )

Supernus Pharmaceuticals Økonomi

Annual 2023
Omsetning: $607.52M
Bruttogevinst: $438.88M (72.24 %)
EPS: $0.0241
FY 2023
Omsetning: $607.52M
Bruttogevinst: $438.88M (72.24 %)
EPS: $0.0241
FY 2022
Omsetning: $667.24M
Bruttogevinst: $580.02M (86.93 %)
EPS: $1.130
FY 2021
Omsetning: $579.78M
Bruttogevinst: $504.71M (87.05 %)
EPS: $1.010

Financial Reports:

No articles found.

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.